Dilated Cardiomyopathy Therapeutics Market size is expected to grow at a CAGR of 6.27% during the forecast period and the market size is expected to reach nearly US$ 234.62 Mn. by 2029. Dilated cardiomyopathy (DCM) is a cardiac disorder in simple words it is caused by an expansion of the heart. The disorder can cause effect on the livers, lungs and other important organs of the body gradually.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.To know about the Research Methodology :- Request Free Sample Report The success of these clinical studies will boost the growth and demand for the dilated cardiomyopathy therapeutics market in forthcoming years. The rising prevalence of congestive heart failure is the major driver for the market for cardiomyopathy therapeutics, but several factors impede the growth of the dilated cardiomyopathy therapeutics market in the coming future. The availability of implantable devices, such as heart pumps, implantable cardioverter defibrillators (ICDs), and pacemakers, and the propitious development of gene therapy will hinder the growth of the dilated cardiomyopathy therapeutics market in the coming future. Additionally, the various side effects related to the usage of DCM drugs and the easier treatment with the help of other devices, which have minimal or nil side effects, will impede the growth of the dilated cardiomyopathy therapeutics market in the forthcoming future. Based on the drug class, Angiotensin II receptor blockers held the leading revenue share of xx% in the market, trailed by beta-blockers. The reason for them acquiring the largest revenue share is their high demand in dilated cardiomyopathy treatment, mainly in the developed regions of Europe and North America. On the other hand, the aldosterone antagonists segment held the highest growth rate on account of the positive effect of the combination of aldosterone antagonists with ACE inhibitors or ARBs for reducing the progress of Duchenne muscular dystrophy (DMD). Region-wise, in terms of revenue, North America accounted for the largest market share of xx% thanks to rising incidences of congestive heart failure and high acceptance of branded drugs. In the U.S., DCM is prevalent in approximately five to eight people out of every 100,000 people. In Canada, heart failure affects over 1% of the total population and is answerable for about 9% of all the deaths. The Asia Pacific and Rest of the World markets are the fastest-growing markets because of rising economic standards, rising disposable income and high demand for generic drugs. The objective of the report is to present comprehensive analysis of global dilated cardiomyopathy therapeutics market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global dilated cardiomyopathy therapeutics market dynamics, structure by analyzing the market segments, and project the global dilated cardiomyopathy therapeutics market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global dilated cardiomyopathy therapeutics market make the report investor’s guide.Scope of the Global Dilated Cardiomyopathy Therapeutics Market: Inquire before buying
Global Dilated Cardiomyopathy Therapeutics Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: US $ 153.2 Mn. Forecast Period 2023 to 2029 CAGR: 6.27% Market Size in 2029: US $ 234.62 Mn. Segments Covered: by Drug Class • Aldosterone antagonists • Angiotensin-converting enzyme (ACE) inhibitors • Angiotensin II receptor blockers (ARBs) • Beta-blockers by Pipeline Drugs • ARRY-797 • ixCELL-DCM • MYDICAR • OR-1 • CAP-1002 Dilated Cardiomyopathy Therapeutics Market, by Region
• North America (United States, Canada and Mexico) • Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) • Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) • Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) • South America (Brazil, Argentina Rest of South America)Dilated Cardiomyopathy Therapeutics Market, Key Players are:
• Array BioPharma, Inc. • AstraZeneca plc. • Celladon Corporation • GlaxoSmithKline plc. • Janssen Pharmaceuticals, Inc. • Merck & Co., Inc. • Novartis International AG • Pfizer, Inc. • Teva Pharmaceutical Industries Ltd • Vericel Corporation • Zensun Shanghai Sci & Tech Co Ltd • Capricor Therapeutics, Inc • t2cure GmbH • MyoKardia • Kasiak Research pvt.ltd Frequently Asked Questions: 1. Which region has the largest share in Global Dilated Cardiomyopathy Therapeutics Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Dilated Cardiomyopathy Therapeutics Market? Ans: The Global Dilated Cardiomyopathy Therapeutics Market is growing at a CAGR of 6.27% during forecasting period 2023-2029. 3. What is scope of the Global Dilated Cardiomyopathy Therapeutics Market report? Ans: Global Dilated Cardiomyopathy Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Dilated Cardiomyopathy Therapeutics Market? Ans: The important key players in the Global Dilated Cardiomyopathy Therapeutics Market are – Array BioPharma, Inc., AstraZeneca plc., Celladon Corporation, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Vericel Corporation, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, t2cure GmbH, MyoKardia, Kasiak Research pvt.ltd. 5. What is the study period of this Market? Ans: The Global Dilated Cardiomyopathy Therapeutics Market is studied from 2022 to 2029.
Global Dilated Cardiomyopathy Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Dilated Cardiomyopathy Therapeutics Market, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Dilated Cardiomyopathy Therapeutics Market Analysis and Forecast 6.1. Global Dilated Cardiomyopathy Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Dilated Cardiomyopathy Therapeutics Market Analysis and Forecast, by Pipeline Drugs 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs 7.4. Global Dilated Cardiomyopathy Therapeutics Market Size (US$ Bn) Forecast, by Pipeline Drugs 7.5. Global Dilated Cardiomyopathy Therapeutics Market Analysis, by Pipeline Drugs 7.6. Global Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis, by Pipeline Drugs 8. Global Dilated Cardiomyopathy Therapeutics Market Analysis and Forecast, by Drug Class 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class 8.4. Global Dilated Cardiomyopathy Therapeutics Market Size (US$ Bn) Forecast, by Drug Class 8.5. Global Dilated Cardiomyopathy Therapeutics Market Analysis, by Drug Class 8.6. Global Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis, by Drug Class 9. Global Dilated Cardiomyopathy Therapeutics Market Analysis, by Region 9.1. Global Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Region 9.2. Global Dilated Cardiomyopathy Therapeutics Market Size (US$ Bn) Forecast, by Region 9.3. Global Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis, by Region 10. North America Dilated Cardiomyopathy Therapeutics Market Analysis 10.1. Key Findings 10.2. North America Dilated Cardiomyopathy Therapeutics Market Overview 10.3. North America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs 10.4. North America Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 10.4.1. ARRY-797 10.4.2. IxCELL-DCM 10.4.3. MYDICAR 10.4.4. OR-1 10.4.5. CAP-1002 10.5. North America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class 10.6. North America Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 10.6.1. Aldosterone antagonists 10.6.2. Angiotensin-converting enzyme (ACE) inhibitors 10.6.3. Angiotensin II receptor blockers (ARBs) 10.6.4. Beta-blockers 10.7. North America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Country 10.8. North America Dilated Cardiomyopathy Therapeutics Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Dilated Cardiomyopathy Therapeutics Market Analysis, by Country 10.10. U.S. Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 10.10.1. ARRY-797 10.10.2. IxCELL-DCM 10.10.3. MYDICAR 10.10.4. OR-1 10.10.5. CAP-1002 10.11. U.S. Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 10.11.1. Aldosterone antagonists 10.11.2. Angiotensin-converting enzyme (ACE) inhibitors 10.11.3. Angiotensin II receptor blockers (ARBs) 10.11.4. Beta-blockers 10.12. Canada Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 10.12.1. ARRY-797 10.12.2. IxCELL-DCM 10.12.3. MYDICAR 10.12.4. OR-1 10.12.5. CAP-1002 10.13. Canada Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 10.13.1. Aldosterone antagonists 10.13.2. Angiotensin-converting enzyme (ACE) inhibitors 10.13.3. Angiotensin II receptor blockers (ARBs) 10.13.4. Beta-blockers 10.14. North America Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis 10.14.1. By Pipeline Drugs 10.14.2. By Drug Class 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Dilated Cardiomyopathy Therapeutics Market Analysis 11.1. Key Findings 11.2. Europe Dilated Cardiomyopathy Therapeutics Market Overview 11.3. Europe Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs 11.4. Europe Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 11.4.1. ARRY-797 11.4.2. IxCELL-DCM 11.4.3. MYDICAR 11.4.4. OR-1 11.4.5. CAP-1002 11.5. Europe Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class 11.6. Europe Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 11.6.1. Aldosterone antagonists 11.6.2. Angiotensin-converting enzyme (ACE) inhibitors 11.6.3. Angiotensin II receptor blockers (ARBs) 11.6.4. Beta-blockers 11.7. Europe Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Country 11.8. Europe Dilated Cardiomyopathy Therapeutics Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Dilated Cardiomyopathy Therapeutics Market Analysis, by Country 11.10. Germany Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 11.10.1. ARRY-797 11.10.2. IxCELL-DCM 11.10.3. MYDICAR 11.10.4. OR-1 11.10.5. CAP-1002 11.11. Germany Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 11.11.1. Aldosterone antagonists 11.11.2. Angiotensin-converting enzyme (ACE) inhibitors 11.11.3. Angiotensin II receptor blockers (ARBs) 11.11.4. Beta-blockers 11.12. U.K. Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 11.12.1. ARRY-797 11.12.2. IxCELL-DCM 11.12.3. MYDICAR 11.12.4. OR-1 11.12.5. CAP-1002 11.13. U.K. Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 11.13.1. Aldosterone antagonists 11.13.2. Angiotensin-converting enzyme (ACE) inhibitors 11.13.3. Angiotensin II receptor blockers (ARBs) 11.13.4. Beta-blockers 11.14. France Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 11.14.1. ARRY-797 11.14.2. IxCELL-DCM 11.14.3. MYDICAR 11.14.4. OR-1 11.14.5. CAP-1002 11.15. France Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 11.15.1. Aldosterone antagonists 11.15.2. Angiotensin-converting enzyme (ACE) inhibitors 11.15.3. Angiotensin II receptor blockers (ARBs) 11.15.4. Beta-blockers 11.16. Italy Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 11.16.1. ARRY-797 11.16.2. IxCELL-DCM 11.16.3. MYDICAR 11.16.4. OR-1 11.16.5. CAP-1002 11.17. Italy Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 11.17.1. Aldosterone antagonists 11.17.2. Angiotensin-converting enzyme (ACE) inhibitors 11.17.3. Angiotensin II receptor blockers (ARBs) 11.17.4. Beta-blockers 11.18. Spain Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 11.18.1. ARRY-797 11.18.2. IxCELL-DCM 11.18.3. MYDICAR 11.18.4. OR-1 11.18.5. CAP-1002 11.19. Spain Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 11.19.1. Aldosterone antagonists 11.19.2. Angiotensin-converting enzyme (ACE) inhibitors 11.19.3. Angiotensin II receptor blockers (ARBs) 11.19.4. Beta-blockers 11.20. Rest of Europe Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 11.20.1. ARRY-797 11.20.2. IxCELL-DCM 11.20.3. MYDICAR 11.20.4. OR-1 11.20.5. CAP-1002 11.21. Rest of Europe Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 11.21.1. Aldosterone antagonists 11.21.2. Angiotensin-converting enzyme (ACE) inhibitors 11.21.3. Angiotensin II receptor blockers (ARBs) 11.21.4. Beta-blockers 11.22. Europe Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis 11.22.1. By Pipeline Drugs 11.22.2. By Drug Class 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Development 12. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Analysis 12.1. Key Findings 12.2. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Overview 12.3. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs 12.4. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 12.4.1. ARRY-797 12.4.2. IxCELL-DCM 12.4.3. MYDICAR 12.4.4. OR-1 12.4.5. CAP-1002 12.5. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class 12.6. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 12.6.1. Aldosterone antagonists 12.6.2. Angiotensin-converting enzyme (ACE) inhibitors 12.6.3. Angiotensin II receptor blockers (ARBs) 12.6.4. Beta-blockers 12.7. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Country 12.8. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Analysis, by Country 12.10. China Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 12.10.1. ARRY-797 12.10.2. IxCELL-DCM 12.10.3. MYDICAR 12.10.4. OR-1 12.10.5. CAP-1002 12.11. China Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 12.11.1. Aldosterone antagonists 12.11.2. Angiotensin-converting enzyme (ACE) inhibitors 12.11.3. Angiotensin II receptor blockers (ARBs) 12.11.4. Beta-blockers 12.12. India Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 12.12.1. ARRY-797 12.12.2. IxCELL-DCM 12.12.3. MYDICAR 12.12.4. OR-1 12.12.5. CAP-1002 12.13. India Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 12.13.1. Aldosterone antagonists 12.13.2. Angiotensin-converting enzyme (ACE) inhibitors 12.13.3. Angiotensin II receptor blockers (ARBs) 12.13.4. Beta-blockers 12.14. Japan Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 12.14.1. ARRY-797 12.14.2. IxCELL-DCM 12.14.3. MYDICAR 12.14.4. OR-1 12.14.5. CAP-1002 12.15. Japan Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 12.15.1. Aldosterone antagonists 12.15.2. Angiotensin-converting enzyme (ACE) inhibitors 12.15.3. Angiotensin II receptor blockers (ARBs) 12.15.4. Beta-blockers 12.16. ASEAN Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 12.16.1. ARRY-797 12.16.2. IxCELL-DCM 12.16.3. MYDICAR 12.16.4. OR-1 12.16.5. CAP-1002 12.17. ASEAN Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 12.17.1. Aldosterone antagonists 12.17.2. Angiotensin-converting enzyme (ACE) inhibitors 12.17.3. Angiotensin II receptor blockers (ARBs) 12.17.4. Beta-blockers 12.18. Rest of Asia Pacific Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 12.18.1. ARRY-797 12.18.2. IxCELL-DCM 12.18.3. MYDICAR 12.18.4. OR-1 12.18.5. CAP-1002 12.19. Rest of Asia Pacific Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 12.19.1. Aldosterone antagonists 12.19.2. Angiotensin-converting enzyme (ACE) inhibitors 12.19.3. Angiotensin II receptor blockers (ARBs) 12.19.4. Beta-blockers 12.20. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis 12.20.1. By Pipeline Drugs 12.20.2. By Drug Class 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Development 13. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Overview 13.3. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs 13.4. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 13.4.1. ARRY-797 13.4.2. IxCELL-DCM 13.4.3. MYDICAR 13.4.4. OR-1 13.4.5. CAP-1002 13.5. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class 13.6. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 13.6.1. Aldosterone antagonists 13.6.2. Angiotensin-converting enzyme (ACE) inhibitors 13.6.3. Angiotensin II receptor blockers (ARBs) 13.6.4. Beta-blockers 13.7. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Country 13.8. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Analysis, by Country 13.10. GCC Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 13.10.1. ARRY-797 13.10.2. IxCELL-DCM 13.10.3. MYDICAR 13.10.4. OR-1 13.10.5. CAP-1002 13.11. GCC Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 13.11.1. Aldosterone antagonists 13.11.2. Angiotensin-converting enzyme (ACE) inhibitors 13.11.3. Angiotensin II receptor blockers (ARBs) 13.11.4. Beta-blockers 13.12. South Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 13.12.1. ARRY-797 13.12.2. IxCELL-DCM 13.12.3. MYDICAR 13.12.4. OR-1 13.12.5. CAP-1002 13.13. South Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 13.13.1. Aldosterone antagonists 13.13.2. Angiotensin-converting enzyme (ACE) inhibitors 13.13.3. Angiotensin II receptor blockers (ARBs) 13.13.4. Beta-blockers 13.14. Rest of Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 13.14.1. ARRY-797 13.14.2. IxCELL-DCM 13.14.3. MYDICAR 13.14.4. OR-1 13.14.5. CAP-1002 13.15. Rest of Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 13.15.1. Aldosterone antagonists 13.15.2. Angiotensin-converting enzyme (ACE) inhibitors 13.15.3. Angiotensin II receptor blockers (ARBs) 13.15.4. Beta-blockers 13.16. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis 13.16.1. By Pipeline Drugs 13.16.2. By Drug Class 13.17. PEST Analysis 13.18. Key Trends 13.19. Key Development 14. South America Dilated Cardiomyopathy Therapeutics Market Analysis 14.1. Key Findings 14.2. South America Dilated Cardiomyopathy Therapeutics Market Overview 14.3. South America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs 14.4. South America Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 14.4.1. ARRY-797 14.4.2. IxCELL-DCM 14.4.3. MYDICAR 14.4.4. OR-1 14.4.5. CAP-1002 14.5. South America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class 14.6. South America Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 14.6.1. Aldosterone antagonists 14.6.2. Angiotensin-converting enzyme (ACE) inhibitors 14.6.3. Angiotensin II receptor blockers (ARBs) 14.6.4. Beta-blockers 14.7. South America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Country 14.8. South America Dilated Cardiomyopathy Therapeutics Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Dilated Cardiomyopathy Therapeutics Market Analysis, by Country 14.10. Brazil Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 14.10.1. ARRY-797 14.10.2. IxCELL-DCM 14.10.3. MYDICAR 14.10.4. OR-1 14.10.5. CAP-1002 14.11. Brazil Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 14.11.1. Aldosterone antagonists 14.11.2. Angiotensin-converting enzyme (ACE) inhibitors 14.11.3. Angiotensin II receptor blockers (ARBs) 14.11.4. Beta-blockers 14.12. Mexico Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 14.12.1. ARRY-797 14.12.2. IxCELL-DCM 14.12.3. MYDICAR 14.12.4. OR-1 14.12.5. CAP-1002 14.13. Mexico Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 14.13.1. Aldosterone antagonists 14.13.2. Angiotensin-converting enzyme (ACE) inhibitors 14.13.3. Angiotensin II receptor blockers (ARBs) 14.13.4. Beta-blockers 14.14. Rest of South America Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs 14.14.1. ARRY-797 14.14.2. IxCELL-DCM 14.14.3. MYDICAR 14.14.4. OR-1 14.14.5. CAP-1002 14.15. Rest of South America Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class 14.15.1. Aldosterone antagonists 14.15.2. Angiotensin-converting enzyme (ACE) inhibitors 14.15.3. Angiotensin II receptor blockers (ARBs) 14.15.4. Beta-blockers 14.16. South America Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis 14.16.1. By Pipeline Drugs 14.16.2. By Drug Class 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Array BioPharma, Inc. 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. AstraZeneca plc. 15.3.3. Celladon Corporation 15.3.4. GlaxoSmithKline plc. 15.3.5. Janssen Pharmaceuticals, Inc. 15.3.6. Merck & Co., Inc. 15.3.7. Novartis International AG 15.3.8. Pfizer, Inc. 15.3.9. Teva Pharmaceutical Industries Ltd 15.3.10. Vericel Corporation 15.3.11. Zensun Shanghai Sci & Tech Co Ltd 15.3.12. Capricor Therapeutics, Inc 15.3.13. t2cure GmbH 15.3.14. MyoKardia 15.3.15. Kasiak Research pvt.ltd 16. Primary Key Insights